search
Back to results

Sodium Bicarbonate in Cardiopulmonary Resuscitation (SB CAT)

Primary Purpose

Sudden Cardiac Arrest

Status
Unknown status
Phase
Phase 4
Locations
Israel
Study Type
Interventional
Intervention
sodium bicarbonate
Sponsored by
Rambam Health Care Campus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sudden Cardiac Arrest focused on measuring cardiac arrest, cardiopulmonary resuscitation, (sodium) bicarbonate, return of spontaneous circulation, outcome

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • patients who suffer Out of hospital, non-traumatic cardiac arrest
  • patients who do not respond to the initial resuscitation efforts (including basic CPR, defibrillation (when indicated) and other appropriate ACLS measures)
  • patients in whom a vascular access (either an IV line or an intraosseous needle) has been obtained
  • patients who have reached the "drugs" step in the ACLS algorithm.

Exclusion Criteria:

  • Patients with known terminal illness
  • Patients with a Do Not Resuscitate (or similar) order
  • Cardiac arrest due to trauma, drug overdose or known intracranial disease
  • Age less than 18 years
  • Known pregnancy
  • Patients in whom 30 minutes or more have passed from collapse to initiation of CPR
  • If collapse time is unknown - patients with obvious death marks
  • Patients with no vascular access (either an IV line or an intraosseous needle)

Sites / Locations

  • Rambam Medical Center
  • Magen David Adom

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Sodium bicarbonate

0.9% NaCl

Arm Description

1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR.

1 ml/kg of 0.9% NaCl (Blinded label)

Outcomes

Primary Outcome Measures

Short-term survival
proportion of patients who achieve return of spontaneous circulation (ROSC) and proportion of patients admitted alive (not requiring CPR) to the hospital's emergency room

Secondary Outcome Measures

Full Information

First Posted
June 16, 2011
Last Updated
November 6, 2011
Sponsor
Rambam Health Care Campus
search

1. Study Identification

Unique Protocol Identification Number
NCT01377337
Brief Title
Sodium Bicarbonate in Cardiopulmonary Resuscitation
Acronym
SB CAT
Official Title
Does the Early Use of Sodium Bicarbonate Improve Results of Cardiopulmonary Resuscitation Following Out-of-Hospital Cardiac Arrest - a Prospective, Controlled Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
November 2011
Overall Recruitment Status
Unknown status
Study Start Date
December 2011 (undefined)
Primary Completion Date
December 2013 (Anticipated)
Study Completion Date
March 2014 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rambam Health Care Campus

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Out-of-hospital cardiac arrests (OHCA) account for over 60% of deaths from coronary artery disease. The annual incidence of OHCA treated by Emergency Medical Systems (EMS) is 41-89 per 100,000 population. Outcome of OHCA and cardiopulmonary resuscitation (CPR) is very poor: Less than 1/3 of the victims regain spontaneous circulation (ROSC), 40-60% of those achieving ROSC suffer significant neurological disability due to brain hypoxia and only 1.7-6.4% are discharged from the hospital. In order to minimize hypoxia time, the primary goal of CPR is to achieve return of spontaneous circulation (ROSC) as fast as possible. Metabolic (lactic) acidosis develops rapidly during CA and is considered detrimental to CPR outcome. Sodium bicarbonate (SB), a generic, commonly used acid buffer, was subjected only to a single, small, prospective controlled trial that found a trend towards improved outcome in prolonged OHCA and CPR. Another study indicated that EMS's that used SB early and often during CPR had significantly higher ROSC rates and better long-term outcome compared with EMS's that used SB more seldom and administered it late in the course of CPR. Aim of the Study: To determine whether early administration of SB during OHCA and CPR improves short-term CPR outcome.
Detailed Description
General: Prospective, randomized, double blinded, placebo-controlled clinical trial. Exception from Informed Consent, under the regulations for the conduction of research in emergency situations, has been approved by the Helsinki Committee of the Rambam Medical Center and by the Supreme Helsinki Committee of the Israeli Ministry of Health. Included will be adult patients who suffer an OHCA, who do not respond to basic CPR and to early defibrillation and in whom advanced CPR is initiated. 1st dose (1 mEq/Kg) of SB/placebo will be administered by Israeli Magen David Adom (MDA) advanced life support (ALS) teams immediately following the first IV epinephrine. SB/placebo vials or syringes will be masked and coded. Calculated sample size is 2130 patients. Study endpoints include only short-term outcome variables - rates of ROSC and of admission to the emergency room. Expected results: Based on previous analysis we expect a 20% improved short-term outcome in the SB treated group. Sample size was calculated accordingly. Importance: Around 2.2 million OHCA's are treated by EMS worldwide annually. Current ROSC rate is ca. 30%. A 20% better short-term outcome will result in over 130,000 additional patients regaining spontaneous circulation annually. Probable implications to Medicine: The use of SB in CPR is controversial. Current International Guidelines for CPR present very reserved recommendations regarding SB use. Results of this study may have a direct impact on the Guidelines and on the conduction of CPR world-wide. Based on the results of this trial, a Phase II trial, researching the effects of early SB administration on long-term outcome (hospital discharge and final neurological outcome) may be warranted and conducted.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sudden Cardiac Arrest
Keywords
cardiac arrest, cardiopulmonary resuscitation, (sodium) bicarbonate, return of spontaneous circulation, outcome

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
2130 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Sodium bicarbonate
Arm Type
Active Comparator
Arm Description
1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR.
Arm Title
0.9% NaCl
Arm Type
Placebo Comparator
Arm Description
1 ml/kg of 0.9% NaCl (Blinded label)
Intervention Type
Drug
Intervention Name(s)
sodium bicarbonate
Intervention Description
1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR. Dose may be repeated every 5-10 minutes up to 3 doses. Note: The Placebo Arm receives 1 ml/Kg of 0.9% NaCl (in a blinded fashion).
Primary Outcome Measure Information:
Title
Short-term survival
Description
proportion of patients who achieve return of spontaneous circulation (ROSC) and proportion of patients admitted alive (not requiring CPR) to the hospital's emergency room
Time Frame
at completion of CPR

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: patients who suffer Out of hospital, non-traumatic cardiac arrest patients who do not respond to the initial resuscitation efforts (including basic CPR, defibrillation (when indicated) and other appropriate ACLS measures) patients in whom a vascular access (either an IV line or an intraosseous needle) has been obtained patients who have reached the "drugs" step in the ACLS algorithm. Exclusion Criteria: Patients with known terminal illness Patients with a Do Not Resuscitate (or similar) order Cardiac arrest due to trauma, drug overdose or known intracranial disease Age less than 18 years Known pregnancy Patients in whom 30 minutes or more have passed from collapse to initiation of CPR If collapse time is unknown - patients with obvious death marks Patients with no vascular access (either an IV line or an intraosseous needle)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Gad Bar-Joseph, Prof.
Phone
972-50-2062115
Email
g_barjoseph@rambam.health.gov.il
First Name & Middle Initial & Last Name or Official Title & Degree
Rachel Gil, RN
Phone
972-50-2064257
Email
r_gil@rambam.health.gov.il
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gad Bar-Joseph
Organizational Affiliation
Rambam Health Care Campus
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rambam Medical Center
City
Haifa
ZIP/Postal Code
31096
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gad Bar-Joseph, Prof.
Email
g_barjoseph@rambam.health.gov.il
Facility Name
Magen David Adom
City
Tel Aviv
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zvi Figenberg, MD
Email
zvif@mdais.co.il

12. IPD Sharing Statement

Learn more about this trial

Sodium Bicarbonate in Cardiopulmonary Resuscitation

We'll reach out to this number within 24 hrs